Back to Search Start Over

A simple nucleic acid amplification assay for the rapid detection of Junín virus in whole blood samples

Authors :
Mario Enrique Lozano
Oscar Grau
Pablo Daniel Ghiringhelli
Víctor Romanowski
Source :
Virus Research. 27:37-53
Publication Year :
1993
Publisher :
Elsevier BV, 1993.

Abstract

Argentine hemorrhagic fever (AHF) is an endemoepidemic disease with cardiovascular, renal and neurologic alterations acquired in the richest farming land in Argentina. It is caused by Junin virus, one of the few human pathogenic arenaviruses. The S RNA of Junin virus has been molecularly cloned and its nucleotide sequence determined in our laboratory. This information was used to develop a rapid nucleic acid-based diagnostic test commensurate with the low viraemia detected in AHF patients. Junin virus-specific cDNA probes labeled using various methods proved insensitive in dot-hybridizations. Therefore, a RT polymerase chain reaction (PCR) was developed using a pair of oligonucleotide primers to reverse-transcribe and amplify the viral S RNA. The amplification of the target sequences was measured by ethidium bromide staining of the DNA fragments after agarose gel electrophoresis. This type of assay allowed the specific detection of Junin virus RNA sequences present in a single infected BHK21 cell over a background of 10 4 uninfected cells. Control reactions were performed on RNA samples extracted from uninfected cells or cells infected with a high multiplicity of LCMV, another arenavirus present in the AHF endemic area. The PCR was first adapted to detect viral RNA in peripheral blood mononuclear cells, described to harbor most of the virus. A simplification of this assay allows the detection of Junin virus in RNA extracted from 100 μl of whole blood using guanidium thiocyanate disruption and acid phenol extraction. Under the conditions described in this paper, it is possible to detect up to 0.01 pfu of Junin virus in a blood sample. An early and rapid laboratory diagnostic test for AHF is important since the only effective therapy that reduces the mortality rate from 30% to less than 1% consists of early treatment with immune plasma.

Details

ISSN :
01681702
Volume :
27
Database :
OpenAIRE
Journal :
Virus Research
Accession number :
edsair.doi.dedup.....3c4d65784d60cae16d7ecc64cec0c9e8